A checklist for medication compliance and persistence studies using retrospective databases
- PMID: 17261111
- DOI: 10.1111/j.1524-4733.2006.00139.x
A checklist for medication compliance and persistence studies using retrospective databases
Abstract
The increasing number of retrospective database studies related to medication compliance and persistence (C&P), and the inherent variability within each, has created a need for improvement in the quality and consistency of medication C&P research. This article stems from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) efforts to develop a checklist of items that should be either included, or at least considered, when a retrospective database analysis of medication compliance or persistence is undertaken. This consensus document outlines a systematic approach to designing or reviewing retrospective database studies of medication C&P. Included in this article are discussions on data sources, measures of C&P, results reporting, and even conflict of interests. If followed, this checklist should improve the consistency and quality of C&P analyses, which in turn will help providers and payers understand the impact of C&P on health outcomes.
Similar articles
-
A framework for planning and critiquing medication compliance and persistence research using prospective study designs.Clin Ther. 2009 Feb;31(2):421-35. doi: 10.1016/j.clinthera.2009.02.021. Clin Ther. 2009. PMID: 19302915 Review.
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.Value Health. 2009 Nov-Dec;12(8):1086-99. doi: 10.1111/j.1524-4733.2009.00605.x. Epub 2009 Sep 10. Value Health. 2009. PMID: 19744291
-
Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.Value Health. 2005 Sep-Oct;8(5):521-33. doi: 10.1111/j.1524-4733.2005.00045.x. Value Health. 2005. PMID: 16176491 Review.
-
Guidelines for pharmacoeconomic and outcomes research fellowship training programs: joint guidelines from the american college of clinical pharmacy and the international society of pharmacoeconomics and outcomes research.Pharmacotherapy. 2008 Dec;28(12):1552. doi: 10.1592/phco.28.12.1552. Pharmacotherapy. 2008. PMID: 19025439
-
Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001.Value Health. 2003 Sep-Oct;6(5):522-31. doi: 10.1046/j.1524-4733.2003.65309.x. Value Health. 2003. PMID: 14627058
Cited by 156 articles
-
Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study.Diabetes Spectr. 2020 Aug;33(3):264-272. doi: 10.2337/ds19-0060. Diabetes Spectr. 2020. PMID: 32848348
-
Risk factors for intensive care admission in children with severe acute asthma in the Netherlands: a prospective multicentre study.ERJ Open Res. 2020 Aug 17;6(3):00126-2020. doi: 10.1183/23120541.00126-2020. eCollection 2020 Jul. ERJ Open Res. 2020. PMID: 32832524 Free PMC article.
-
The Need to Develop Standard Measures of Patient Adherence for Big Data: Viewpoint.J Med Internet Res. 2020 Aug 27;22(8):e18150. doi: 10.2196/18150. J Med Internet Res. 2020. PMID: 32663138 Free PMC article.
-
Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.Adv Ther. 2020 Aug;37(8):3584-3605. doi: 10.1007/s12325-020-01412-z. Epub 2020 Jul 7. Adv Ther. 2020. PMID: 32638205 Free PMC article.
-
Challenges and Approaches to Measuring Repeat Fecal Immunochemical Test for Colorectal Cancer Screening.Cancer Epidemiol Biomarkers Prev. 2020 Aug;29(8):1557-1563. doi: 10.1158/1055-9965.EPI-20-0230. Epub 2020 May 26. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32457184
MeSH terms
LinkOut - more resources
Full Text Sources
